The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)
Identifieur interne : 001198 ( Istex/Corpus ); précédent : 001197; suivant : 001199The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)
Auteurs : C. Delcourt ; Y. Huang ; J. Wang ; E. Heeley ; R. Lindley ; C. Stapf ; C. Tzourio ; H. Arima ; M. Parsons ; J. Sun ; B. Neal ; J. Chalmers ; C. AndersonSource :
- International Journal of Stroke [ 1747-4930 ] ; 2010-04.
English descriptors
- KwdEn :
- Absolute difference, Active treatment, Acute intracerebral hemorrhage, Acute stroke, American heart association, April, Blood pressure, Blood treatment, Christophe tzourio, Clear evidence, Clinical outcome, Clinical practice, Clinical research unit, Clinical trial, Clinical trial protocols, Control group, Craig anderson, Deep coma, Definite indication, Delcourt, Dependency, European stroke organization, Exclusion criteria, George institute, Glasgow coma scale, Haematoma, Haematoma expansion, Haematoma growth, Haemorrhage, Haemorrhage trial, Health stroke scale, High likelihood, High rates, Hospital discharge, Imaging technology, Intensive blood pressure reduction, Intensive care unit, Intensive group, Intensive regimen, Interact2, Interact2 study, International health, Intracerebral, Intracerebral haemorrhage, Jiguang wang, Journal compilation, Lancet neurol, Lariboisiere hospital, Mmhg, More cases, Oral antihypertensive therapy, Outcome assessments, Physical function, Pilot phase, Pilot study, Poor outcome, Primary outcome, Protocol, Randomisation, Randomised, Rankin scale, Recurrent stroke, Relative reduction, Relative risk reduction, Responsible physician, Royal prince alfred hospital, Sample size, Secondary outcomes, Spontaneous intracerebral haemorrhage, Spontaneous intracerebral hemorrhage, Stroke, Structural abnormality, Surgical evacuation, Systematic review, Systolic, Systolic blood pressure, Target systolic, Telephone interview, Treatment effect, Treatment groups, World stroke organization, Yining huang.
- Teeft :
- Absolute difference, Active treatment, Acute intracerebral hemorrhage, Acute stroke, American heart association, April, Blood pressure, Blood treatment, Christophe tzourio, Clear evidence, Clinical outcome, Clinical practice, Clinical research unit, Clinical trial, Clinical trial protocols, Control group, Craig anderson, Deep coma, Definite indication, Delcourt, Dependency, European stroke organization, Exclusion criteria, George institute, Glasgow coma scale, Haematoma, Haematoma expansion, Haematoma growth, Haemorrhage, Haemorrhage trial, Health stroke scale, High likelihood, High rates, Hospital discharge, Imaging technology, Intensive blood pressure reduction, Intensive care unit, Intensive group, Intensive regimen, Interact2, Interact2 study, International health, Intracerebral, Intracerebral haemorrhage, Jiguang wang, Journal compilation, Lancet neurol, Lariboisiere hospital, Mmhg, More cases, Oral antihypertensive therapy, Outcome assessments, Physical function, Pilot phase, Pilot study, Poor outcome, Primary outcome, Protocol, Randomisation, Randomised, Rankin scale, Recurrent stroke, Relative reduction, Relative risk reduction, Responsible physician, Royal prince alfred hospital, Sample size, Secondary outcomes, Spontaneous intracerebral haemorrhage, Spontaneous intracerebral hemorrhage, Stroke, Structural abnormality, Surgical evacuation, Systematic review, Systolic, Systolic blood pressure, Target systolic, Telephone interview, Treatment effect, Treatment groups, World stroke organization, Yining huang.
Abstract
Rationale: The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure lowering and effects on haematoma expansion within 6 h of onset of intracerebral haemorrhage. This article describes the design of the second, main phase, INTERACT2.
Url:
DOI: 10.1111/j.1747-4949.2010.00415.x
Links to Exploration step
ISTEX:5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title><author><name sortKey="Delcourt, C" sort="Delcourt, C" uniqKey="Delcourt C" first="C." last="Delcourt">C. Delcourt</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Huang, Y" sort="Huang, Y" uniqKey="Huang Y" first="Y." last="Huang">Y. Huang</name><affiliation><mods:affiliation>Department of Neurology, Peking University First Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Wang, J" sort="Wang, J" uniqKey="Wang J" first="J." last="Wang">J. Wang</name><affiliation><mods:affiliation>Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China</mods:affiliation></affiliation></author><author><name sortKey="Heeley, E" sort="Heeley, E" uniqKey="Heeley E" first="E." last="Heeley">E. Heeley</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Lindley, R" sort="Lindley, R" uniqKey="Lindley R" first="R." last="Lindley">R. Lindley</name><affiliation><mods:affiliation>Sydney Medical School – Western, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Stapf, C" sort="Stapf, C" uniqKey="Stapf C" first="C." last="Stapf">C. Stapf</name><affiliation><mods:affiliation>Department of Neurology, European Regional Coordinating Centre, Clinical Research Unit, Lariboisière Hospital, APHP, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Unit 708, APHP, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name><affiliation><mods:affiliation>INSERM Unit 708, APHP, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Arima, H" sort="Arima, H" uniqKey="Arima H" first="H." last="Arima">H. Arima</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Parsons, M" sort="Parsons, M" uniqKey="Parsons M" first="M." last="Parsons">M. Parsons</name><affiliation><mods:affiliation>John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Sun, J" sort="Sun, J" uniqKey="Sun J" first="J." last="Sun">J. Sun</name><affiliation><mods:affiliation>The George Institute, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Neal, B" sort="Neal, B" uniqKey="Neal B" first="B." last="Neal">B. Neal</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Chalmers, J" sort="Chalmers, J" uniqKey="Chalmers J" first="J." last="Chalmers">J. Chalmers</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Anderson, C" sort="Anderson, C" uniqKey="Anderson C" first="C." last="Anderson">C. Anderson</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: canderson@george.org.au</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1747-4949.2010.00415.x</idno><idno type="url">https://api.istex.fr/document/5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001198</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001198</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title><author><name sortKey="Delcourt, C" sort="Delcourt, C" uniqKey="Delcourt C" first="C." last="Delcourt">C. Delcourt</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Huang, Y" sort="Huang, Y" uniqKey="Huang Y" first="Y." last="Huang">Y. Huang</name><affiliation><mods:affiliation>Department of Neurology, Peking University First Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Wang, J" sort="Wang, J" uniqKey="Wang J" first="J." last="Wang">J. Wang</name><affiliation><mods:affiliation>Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China</mods:affiliation></affiliation></author><author><name sortKey="Heeley, E" sort="Heeley, E" uniqKey="Heeley E" first="E." last="Heeley">E. Heeley</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Lindley, R" sort="Lindley, R" uniqKey="Lindley R" first="R." last="Lindley">R. Lindley</name><affiliation><mods:affiliation>Sydney Medical School – Western, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Stapf, C" sort="Stapf, C" uniqKey="Stapf C" first="C." last="Stapf">C. Stapf</name><affiliation><mods:affiliation>Department of Neurology, European Regional Coordinating Centre, Clinical Research Unit, Lariboisière Hospital, APHP, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Unit 708, APHP, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name><affiliation><mods:affiliation>INSERM Unit 708, APHP, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Arima, H" sort="Arima, H" uniqKey="Arima H" first="H." last="Arima">H. Arima</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Parsons, M" sort="Parsons, M" uniqKey="Parsons M" first="M." last="Parsons">M. Parsons</name><affiliation><mods:affiliation>John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Sun, J" sort="Sun, J" uniqKey="Sun J" first="J." last="Sun">J. Sun</name><affiliation><mods:affiliation>The George Institute, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Neal, B" sort="Neal, B" uniqKey="Neal B" first="B." last="Neal">B. Neal</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Chalmers, J" sort="Chalmers, J" uniqKey="Chalmers J" first="J." last="Chalmers">J. Chalmers</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation></author><author><name sortKey="Anderson, C" sort="Anderson, C" uniqKey="Anderson C" first="C." last="Anderson">C. Anderson</name><affiliation><mods:affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: canderson@george.org.au</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Stroke</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF STROKE</title><idno type="ISSN">1747-4930</idno><idno type="eISSN">1747-4949</idno><imprint><biblScope unit="vol">5</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="110">110</biblScope><biblScope unit="page" to="116">116</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-04">2010-04</date></imprint><idno type="ISSN">1747-4930</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1747-4930</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absolute difference</term><term>Active treatment</term><term>Acute intracerebral hemorrhage</term><term>Acute stroke</term><term>American heart association</term><term>April</term><term>Blood pressure</term><term>Blood treatment</term><term>Christophe tzourio</term><term>Clear evidence</term><term>Clinical outcome</term><term>Clinical practice</term><term>Clinical research unit</term><term>Clinical trial</term><term>Clinical trial protocols</term><term>Control group</term><term>Craig anderson</term><term>Deep coma</term><term>Definite indication</term><term>Delcourt</term><term>Dependency</term><term>European stroke organization</term><term>Exclusion criteria</term><term>George institute</term><term>Glasgow coma scale</term><term>Haematoma</term><term>Haematoma expansion</term><term>Haematoma growth</term><term>Haemorrhage</term><term>Haemorrhage trial</term><term>Health stroke scale</term><term>High likelihood</term><term>High rates</term><term>Hospital discharge</term><term>Imaging technology</term><term>Intensive blood pressure reduction</term><term>Intensive care unit</term><term>Intensive group</term><term>Intensive regimen</term><term>Interact2</term><term>Interact2 study</term><term>International health</term><term>Intracerebral</term><term>Intracerebral haemorrhage</term><term>Jiguang wang</term><term>Journal compilation</term><term>Lancet neurol</term><term>Lariboisiere hospital</term><term>Mmhg</term><term>More cases</term><term>Oral antihypertensive therapy</term><term>Outcome assessments</term><term>Physical function</term><term>Pilot phase</term><term>Pilot study</term><term>Poor outcome</term><term>Primary outcome</term><term>Protocol</term><term>Randomisation</term><term>Randomised</term><term>Rankin scale</term><term>Recurrent stroke</term><term>Relative reduction</term><term>Relative risk reduction</term><term>Responsible physician</term><term>Royal prince alfred hospital</term><term>Sample size</term><term>Secondary outcomes</term><term>Spontaneous intracerebral haemorrhage</term><term>Spontaneous intracerebral hemorrhage</term><term>Stroke</term><term>Structural abnormality</term><term>Surgical evacuation</term><term>Systematic review</term><term>Systolic</term><term>Systolic blood pressure</term><term>Target systolic</term><term>Telephone interview</term><term>Treatment effect</term><term>Treatment groups</term><term>World stroke organization</term><term>Yining huang</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Absolute difference</term><term>Active treatment</term><term>Acute intracerebral hemorrhage</term><term>Acute stroke</term><term>American heart association</term><term>April</term><term>Blood pressure</term><term>Blood treatment</term><term>Christophe tzourio</term><term>Clear evidence</term><term>Clinical outcome</term><term>Clinical practice</term><term>Clinical research unit</term><term>Clinical trial</term><term>Clinical trial protocols</term><term>Control group</term><term>Craig anderson</term><term>Deep coma</term><term>Definite indication</term><term>Delcourt</term><term>Dependency</term><term>European stroke organization</term><term>Exclusion criteria</term><term>George institute</term><term>Glasgow coma scale</term><term>Haematoma</term><term>Haematoma expansion</term><term>Haematoma growth</term><term>Haemorrhage</term><term>Haemorrhage trial</term><term>Health stroke scale</term><term>High likelihood</term><term>High rates</term><term>Hospital discharge</term><term>Imaging technology</term><term>Intensive blood pressure reduction</term><term>Intensive care unit</term><term>Intensive group</term><term>Intensive regimen</term><term>Interact2</term><term>Interact2 study</term><term>International health</term><term>Intracerebral</term><term>Intracerebral haemorrhage</term><term>Jiguang wang</term><term>Journal compilation</term><term>Lancet neurol</term><term>Lariboisiere hospital</term><term>Mmhg</term><term>More cases</term><term>Oral antihypertensive therapy</term><term>Outcome assessments</term><term>Physical function</term><term>Pilot phase</term><term>Pilot study</term><term>Poor outcome</term><term>Primary outcome</term><term>Protocol</term><term>Randomisation</term><term>Randomised</term><term>Rankin scale</term><term>Recurrent stroke</term><term>Relative reduction</term><term>Relative risk reduction</term><term>Responsible physician</term><term>Royal prince alfred hospital</term><term>Sample size</term><term>Secondary outcomes</term><term>Spontaneous intracerebral haemorrhage</term><term>Spontaneous intracerebral hemorrhage</term><term>Stroke</term><term>Structural abnormality</term><term>Surgical evacuation</term><term>Systematic review</term><term>Systolic</term><term>Systolic blood pressure</term><term>Target systolic</term><term>Telephone interview</term><term>Treatment effect</term><term>Treatment groups</term><term>World stroke organization</term><term>Yining huang</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Rationale: The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure lowering and effects on haematoma expansion within 6 h of onset of intracerebral haemorrhage. This article describes the design of the second, main phase, INTERACT2.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>mmhg</json:string><json:string>systolic</json:string><json:string>haematoma</json:string><json:string>randomised</json:string><json:string>intracerebral</json:string><json:string>randomisation</json:string><json:string>haemorrhage</json:string><json:string>blood pressure</json:string><json:string>interact2</json:string><json:string>journal compilation</json:string><json:string>delcourt</json:string><json:string>april</json:string><json:string>world stroke organization</json:string><json:string>george institute</json:string><json:string>clinical trial protocols</json:string><json:string>international health</json:string><json:string>acute stroke</json:string><json:string>pilot phase</json:string><json:string>intracerebral haemorrhage</json:string><json:string>poor outcome</json:string><json:string>rankin scale</json:string><json:string>primary outcome</json:string><json:string>recurrent stroke</json:string><json:string>haematoma growth</json:string><json:string>intensive group</json:string><json:string>royal prince alfred hospital</json:string><json:string>interact2 study</json:string><json:string>exclusion criteria</json:string><json:string>sample size</json:string><json:string>hospital discharge</json:string><json:string>acute intracerebral hemorrhage</json:string><json:string>haematoma expansion</json:string><json:string>pilot study</json:string><json:string>relative risk reduction</json:string><json:string>high likelihood</json:string><json:string>protocol</json:string><json:string>surgical evacuation</json:string><json:string>secondary outcomes</json:string><json:string>more cases</json:string><json:string>clinical trial</json:string><json:string>high rates</json:string><json:string>systematic review</json:string><json:string>oral antihypertensive therapy</json:string><json:string>lancet neurol</json:string><json:string>control group</json:string><json:string>american heart association</json:string><json:string>european stroke organization</json:string><json:string>clinical practice</json:string><json:string>lariboisiere hospital</json:string><json:string>clinical research unit</json:string><json:string>clinical outcome</json:string><json:string>craig anderson</json:string><json:string>intensive care unit</json:string><json:string>treatment groups</json:string><json:string>clear evidence</json:string><json:string>structural abnormality</json:string><json:string>glasgow coma scale</json:string><json:string>deep coma</json:string><json:string>blood treatment</json:string><json:string>physical function</json:string><json:string>target systolic</json:string><json:string>responsible physician</json:string><json:string>definite indication</json:string><json:string>spontaneous intracerebral haemorrhage</json:string><json:string>intensive regimen</json:string><json:string>active treatment</json:string><json:string>outcome assessments</json:string><json:string>telephone interview</json:string><json:string>health stroke scale</json:string><json:string>imaging technology</json:string><json:string>systolic blood pressure</json:string><json:string>haemorrhage trial</json:string><json:string>intensive blood pressure reduction</json:string><json:string>absolute difference</json:string><json:string>relative reduction</json:string><json:string>treatment effect</json:string><json:string>yining huang</json:string><json:string>christophe tzourio</json:string><json:string>jiguang wang</json:string><json:string>spontaneous intracerebral hemorrhage</json:string><json:string>stroke</json:string><json:string>dependency</json:string></teeft></keywords><author><json:item><name>C. Delcourt</name><affiliations><json:string>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</json:string></affiliations></json:item><json:item><name>Y. Huang</name><affiliations><json:string>Department of Neurology, Peking University First Hospital, Beijing, China</json:string></affiliations></json:item><json:item><name>J. Wang</name><affiliations><json:string>Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China</json:string></affiliations></json:item><json:item><name>E. Heeley</name><affiliations><json:string>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</json:string></affiliations></json:item><json:item><name>R. Lindley</name><affiliations><json:string>Sydney Medical School – Western, University of Sydney, Sydney, NSW, Australia</json:string></affiliations></json:item><json:item><name>C. Stapf</name><affiliations><json:string>Department of Neurology, European Regional Coordinating Centre, Clinical Research Unit, Lariboisière Hospital, APHP, Paris, France</json:string><json:string>INSERM Unit 708, APHP, Paris, France</json:string></affiliations></json:item><json:item><name>C. Tzourio</name><affiliations><json:string>INSERM Unit 708, APHP, Paris, France</json:string></affiliations></json:item><json:item><name>H. Arima</name><affiliations><json:string>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</json:string></affiliations></json:item><json:item><name>M. Parsons</name><affiliations><json:string>John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia</json:string></affiliations></json:item><json:item><name>J. Sun</name><affiliations><json:string>The George Institute, Beijing, China</json:string></affiliations></json:item><json:item><name>B. Neal</name><affiliations><json:string>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</json:string></affiliations></json:item><json:item><name>J. Chalmers</name><affiliations><json:string>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</json:string></affiliations></json:item><json:item><name>C. Anderson</name><affiliations><json:string>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</json:string><json:string>E-mail: canderson@george.org.au</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>blood pressure</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hypertension</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>INTERACT</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>intracerebral haemorrhage</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>stroke</value></json:item></subject><articleId><json:string>IJS415</json:string></articleId><arkIstex>ark:/67375/WNG-HBDH7569-X</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Rationale: The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure lowering and effects on haematoma expansion within 6 h of onset of intracerebral haemorrhage. This article describes the design of the second, main phase, INTERACT2.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>41</abstractWordCount><abstractCharCount>288</abstractCharCount><keywordCount>6</keywordCount><score>7.166</score><pdfWordCount>4674</pdfWordCount><pdfCharCount>29083</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize></qualityIndicators><title>The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title><pmid><json:string>20446945</json:string></pmid><corporate><json:item><name>for the INTERACT2 Investigators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><title>International Journal of Stroke</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1747-4949</json:string></doi><issn><json:string>1747-4930</json:string></issn><eissn><json:string>1747-4949</json:string></eissn><publisherId><json:string>IJS</json:string></publisherId><volume>5</volume><issue>2</issue><pages><first>110</first><last>116</last><total>7</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2473</json:string><json:string>2012</json:string><json:string>2010</json:string></date><geogName></geogName><orgName><json:string>George Institute for International Health</json:string><json:string>John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia</json:string><json:string>National Institutes of Health Stroke Scale</json:string><json:string>India, Pakistan</json:string><json:string>University of Sydney</json:string><json:string>MIStar User Manual Melbourne.</json:string><json:string>George Institute India</json:string><json:string>Australia, China</json:string><json:string>George Institute China</json:string><json:string>NIHSS</json:string><json:string>Hospital, Beijing, China</json:string><json:string>Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China</json:string><json:string>George Institute for International Health, Royal Prince</json:string><json:string>Clinical Research Unit, Lariboisiere Hospital, APHP, Paris, France</json:string><json:string>Department of Neurology, European Regional Coordinating Centre</json:string><json:string>George Institute for International Health of the University of Sydney and Royal Prince</json:string><json:string>National Institute of Health Stroke Scale</json:string><json:string>Department of Neurology, Peking University</json:string><json:string>European Stroke Organization</json:string><json:string>American Heart Association</json:string><json:string>Research Unit of Lariboisiere Hospital</json:string><json:string>Australia, China and Korea</json:string><json:string>George Institute, Beijing, China Conflict</json:string><json:string>The International</json:string><json:string>World Stroke Organization International Journal of Stroke Vol</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Mariana Zimmermann</json:string><json:string>J. Chalmers</json:string><json:string>Angel Chamorro</json:string><json:string>Jiguang</json:string><json:string>Jian Sun</json:string><json:string>Lauri Soinne</json:string><json:string>Pablo Lavados</json:string><json:string>Stefano Ricci</json:string><json:string>Ying Shu</json:string><json:string>Claiborne Johnston</json:string><json:string>Christian Stapf</json:string><json:string>Nan Li</json:string><json:string>Qiang</json:string><json:string>Craig Anderson</json:string><json:string>Erich Schmutzhard</json:string><json:string>Jose Ferro</json:string><json:string>Alfred Hospital</json:string><json:string>B. Neal</json:string><json:string>Richard Lindley</json:string><json:string>E. Heeley</json:string><json:string>Andres Moles</json:string><json:string>Cecile Dert</json:string><json:string>Chen Xiaoying</json:string><json:string>C. Tzourio</json:string><json:string>J. Wang</json:string><json:string>Gisele Silva</json:string><json:string>Stephen Davis</json:string><json:string>J. Sun</json:string><json:string>Rankin Score</json:string><json:string>Li Shunwei</json:string><json:string>Eric Vicaut</json:string><json:string>Emma Heeley</json:string><json:string>The</json:string><json:string>Craig AndersonÃ</json:string><json:string>Ronny Beer</json:string><json:string>Investigator</json:string><json:string>John Chalmers</json:string><json:string>Laurent Billot</json:string><json:string>Karin Klijn</json:string><json:string>R. Lindley</json:string><json:string>C. Stapf</json:string><json:string>Patricia Redondo</json:string><json:string>Yining Huang</json:string><json:string>Stephane Heritier</json:string><json:string>Bruce Neal</json:string><json:string>John Simes</json:string><json:string>J. Estol</json:string><json:string>Sofiane Kabla</json:string><json:string>Konrad Jamrozik</json:string><json:string>Y. Huang</json:string><json:string>Mark Parsons</json:string><json:string>Candice Delcourt</json:string><json:string>C. Anderson</json:string><json:string>Christophe Tzourio</json:string><json:string>Lewis Morgenstern</json:string><json:string>H. Arima</json:string><json:string>Marcel Arnold</json:string><json:string>M. Parsons</json:string><json:string>Rankin Scale</json:string><json:string>Alejandro Rabinstein</json:string></persName><placeName><json:string>Paris</json:string><json:string>Switzerland</json:string><json:string>Germany</json:string><json:string>United States</json:string><json:string>Finland</json:string><json:string>Australia</json:string><json:string>Chile</json:string><json:string>Brazil</json:string><json:string>Beijing</json:string><json:string>Austria</json:string><json:string>Melbourne</json:string><json:string>Argentina</json:string><json:string>American</json:string><json:string>India</json:string><json:string>China</json:string><json:string>Glasgow</json:string><json:string>Hyderabad</json:string><json:string>Portugal</json:string><json:string>France</json:string><json:string>Italy</json:string><json:string>Spain</json:string><json:string>Sydney</json:string><json:string>Belgium</json:string><json:string>Netherlands</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>October 2008</json:string><json:string>C. Delcourt et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-HBDH7569-X</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - peripheral vascular disease</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - neurology & neurosurgery</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Neuroscience</json:string><json:string>3 - Neurology</json:string></scopus></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1111/j.1747-4949.2010.00415.x</json:string></doi><id>5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><licence>© 2010 The Authors. Journal compilation © 2010 World Stroke Organization</licence></availability><date type="published" when="2010-04"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title><author xml:id="author-0000"><persName><forename type="first">C.</forename><surname>Delcourt</surname></persName><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Y.</forename><surname>Huang</surname></persName><affiliation>Department of Neurology, Peking University First Hospital, Beijing, China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">J.</forename><surname>Wang</surname></persName><affiliation>Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">E.</forename><surname>Heeley</surname></persName><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">R.</forename><surname>Lindley</surname></persName><affiliation>Sydney Medical School – Western, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">C.</forename><surname>Stapf</surname></persName><affiliation>Department of Neurology, European Regional Coordinating Centre, Clinical Research Unit, Lariboisière Hospital, APHP, Paris, France<address><country key="FR"></country></address></affiliation><affiliation>INSERM Unit 708, APHP, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">C.</forename><surname>Tzourio</surname></persName><affiliation>INSERM Unit 708, APHP, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">H.</forename><surname>Arima</surname></persName><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">M.</forename><surname>Parsons</surname></persName><affiliation>John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0009"><persName><forename type="first">J.</forename><surname>Sun</surname></persName><affiliation>The George Institute, Beijing, China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0010"><persName><forename type="first">B.</forename><surname>Neal</surname></persName><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0011"><persName><forename type="first">J.</forename><surname>Chalmers</surname></persName><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0012" role="corresp"><persName><forename type="first">C.</forename><surname>Anderson</surname></persName><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation><affiliation>Craig Anderson*, The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, PO Box M201, Missenden Road, Sydney, NSW 2050, Australia. E‐mail: canderson@george.org.au</affiliation></author><author xml:id="author-0013"><author><orgName>for the INTERACT2 Investigators</orgName></author><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia<address><country key="AU"></country></address></affiliation></author><idno type="istex">5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25</idno><idno type="ark">ark:/67375/WNG-HBDH7569-X</idno><idno type="DOI">10.1111/j.1747-4949.2010.00415.x</idno><idno type="unit">IJS415</idno><idno type="supplier">415</idno><idno type="toTypesetVersion">file:IJS.IJS415.pdf</idno></analytic><monogr><title level="j" type="main">International Journal of Stroke</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF STROKE</title><idno type="pISSN">1747-4930</idno><idno type="eISSN">1747-4949</idno><idno type="book-DOI">10.1111/(ISSN)1747-4949</idno><idno type="book-part-DOI">10.1111/ijs.2010.5.issue-2</idno><idno type="product">IJS</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">5</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="110">110</biblScope><biblScope unit="page" to="116">116</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-04"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Rationale: </hi> The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure lowering and effects on haematoma expansion within 6 h of onset of intracerebral haemorrhage. This article describes the design of the second, main phase, INTERACT2.</p><p><hi rend="bold">Aims: </hi> To compare the effects of a management strategy of early intensive blood pressure lowering with a more conservative guideline‐based blood pressure management policy in patients with acute intracerebral hemorrhage.</p><p><hi rend="bold">Design: </hi> INTERACT2 is a prospective, randomized, open label, assessor‐blinded end‐point (PROBE). Patients with a systolic blood pressure greater than 150 mmHg and no definite indication for or contraindication to blood pressure‐lowering treatment are centrally randomised to either of two treatment groups within 6 h onset of intracerebral haemorrhage. Those allocated to intensive blood pressure lowering will receive primarily intravenous, hypotensive agents to achieve a systolic blood pressure target of <140 mmHg within 1 h of randomisation and to maintain this level for up to 7 days in hospital. The control group will receive blood pressure‐lowering treatment to a target systolic blood pressure of <180 mmHg. Both groups are to receive similar acute stroke unit care, therapy and active management. Oral antihypertensive therapy is recommended in patients before hospital discharge with a long‐term systolic blood pressure goal of 140 mmHg according to secondary stroke prevention guidelines. A projected 2800 subjects are to be enrolled from approximately 140 centres worldwide to provide 90% power (<hi rend="italic">α</hi> 0·05) to detect a 14% difference in the risk of death and dependency between the groups, which equates to one or more cases of a poor outcome prevented in every 15 patients treated.</p><p><hi rend="bold">Study outcomes: </hi> The primary outcome is the combined end‐point of death and dependency according to the modified Rankin Scale at 90 days. The secondary outcomes are the separate components of the primary end‐point in patients treated <4 hours of ICH onset, grades of physical function on the modified Rankin Scale, health‐related quality of life on the EuroQoL, recurrent stroke and other vascular events, days of hospitalisation, requirement for permanent residential care and unexpected serious adverse events. The study is registered under NCT00716079, ISRCTN73916115 and ACTRN12608000362392.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">blood pressure</term><term xml:id="k2">clinical trial</term><term xml:id="k3">hypertension</term><term xml:id="k4">INTERACT</term><term xml:id="k5">intracerebral haemorrhage</term><term xml:id="k6">stroke</term></keywords><keywords rend="tocHeading1"><term>Clinical trial protocols</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1747-4949</doi><issn type="print">1747-4930</issn><issn type="electronic">1747-4949</issn><idGroup><id type="product" value="IJS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="INTERNATIONAL JOURNAL OF STROKE">International Journal of Stroke</title></titleGroup></publicationMeta><publicationMeta level="part" position="04002"><doi origin="wiley">10.1111/ijs.2010.5.issue-2</doi><numberingGroup><numbering type="journalVolume" number="5">5</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="2010-04">April 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="10" status="forIssue"><doi origin="wiley">10.1111/j.1747-4949.2010.00415.x</doi><idGroup><id type="unit" value="IJS415"></id><id type="supplier" value="415"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="tocHeading1">Clinical trial protocols</title></titleGroup><copyright>© 2010 The Authors. Journal compilation © 2010 World Stroke Organization</copyright><eventGroup><event type="firstOnline" date="2010-03-07"></event><event type="publishedOnlineFinalForm" date="2010-03-07"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-12"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-28"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="110">110</numbering><numbering type="pageLast" number="116">116</numbering></numberingGroup><correspondenceTo> Craig Anderson<sup>*</sup>, The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, PO Box M201, Missenden Road, Sydney, NSW 2050, Australia. E‐mail: <email normalForm="canderson@george.org.au">canderson@george.org.au</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:IJS.IJS415.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="22"></count><count type="wordTotal" number="5342"></count><count type="linksCrossRef" number="39"></count></countGroup><titleGroup><title type="main">The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title><title type="shortAuthors">C. Delcourt <i>et al.</i></title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>C.</givenNames><familyName>Delcourt</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Y.</givenNames><familyName>Huang</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>J.</givenNames><familyName>Wang</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>E.</givenNames><familyName>Heeley</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a4"><personName><givenNames>R.</givenNames><familyName>Lindley</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a5 #a6"><personName><givenNames>C.</givenNames><familyName>Stapf</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a6"><personName><givenNames>C.</givenNames><familyName>Tzourio</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1"><personName><givenNames>H.</givenNames><familyName>Arima</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a7"><personName><givenNames>M.</givenNames><familyName>Parsons</familyName></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#a8"><personName><givenNames>J.</givenNames><familyName>Sun</familyName></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#a1"><personName><givenNames>B.</givenNames><familyName>Neal</familyName></personName></creator><creator creatorRole="author" xml:id="cr12" affiliationRef="#a1"><personName><givenNames>J.</givenNames><familyName>Chalmers</familyName></personName></creator><creator creatorRole="author" xml:id="cr13" affiliationRef="#a1" corresponding="yes"><personName><givenNames>C.</givenNames><familyName>Anderson</familyName></personName></creator><creator creatorRole="author" xml:id="cr14" affiliationRef="#a1"><groupName>for the INTERACT2 Investigators</groupName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="AU"><unparsedAffiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="CN"><unparsedAffiliation>Department of Neurology, Peking University First Hospital, Beijing, China</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="CN"><unparsedAffiliation>Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="AU"><unparsedAffiliation>Sydney Medical School – Western, University of Sydney, Sydney, NSW, Australia</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="FR"><unparsedAffiliation>Department of Neurology, European Regional Coordinating Centre, Clinical Research Unit, Lariboisière Hospital, APHP, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="a6" countryCode="FR"><unparsedAffiliation>INSERM Unit 708, APHP, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="a7" countryCode="AU"><unparsedAffiliation>John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia</unparsedAffiliation></affiliation><affiliation xml:id="a8" countryCode="CN"><unparsedAffiliation>The George Institute, Beijing, China</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">blood pressure</keyword><keyword xml:id="k2">clinical trial</keyword><keyword xml:id="k3">hypertension</keyword><keyword xml:id="k4">INTERACT</keyword><keyword xml:id="k5">intracerebral haemorrhage</keyword><keyword xml:id="k6">stroke</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Rationale: </b> The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure lowering and effects on haematoma expansion within 6 h of onset of intracerebral haemorrhage. This article describes the design of the second, main phase, INTERACT2.</p><p><b>Aims: </b> To compare the effects of a management strategy of early intensive blood pressure lowering with a more conservative guideline‐based blood pressure management policy in patients with acute intracerebral hemorrhage.</p><p><b>Design: </b> INTERACT2 is a prospective, randomized, open label, assessor‐blinded end‐point (PROBE). Patients with a systolic blood pressure greater than 150 mmHg and no definite indication for or contraindication to blood pressure‐lowering treatment are centrally randomised to either of two treatment groups within 6 h onset of intracerebral haemorrhage. Those allocated to intensive blood pressure lowering will receive primarily intravenous, hypotensive agents to achieve a systolic blood pressure target of <140 mmHg within 1 h of randomisation and to maintain this level for up to 7 days in hospital. The control group will receive blood pressure‐lowering treatment to a target systolic blood pressure of <180 mmHg. Both groups are to receive similar acute stroke unit care, therapy and active management. Oral antihypertensive therapy is recommended in patients before hospital discharge with a long‐term systolic blood pressure goal of 140 mmHg according to secondary stroke prevention guidelines. A projected 2800 subjects are to be enrolled from approximately 140 centres worldwide to provide 90% power (<i>α</i> 0·05) to detect a 14% difference in the risk of death and dependency between the groups, which equates to one or more cases of a poor outcome prevented in every 15 patients treated.</p><p><b>Study outcomes: </b> The primary outcome is the combined end‐point of death and dependency according to the modified Rankin Scale at 90 days. The secondary outcomes are the separate components of the primary end‐point in patients treated <4 hours of ICH onset, grades of physical function on the modified Rankin Scale, health‐related quality of life on the EuroQoL, recurrent stroke and other vascular events, days of hospitalisation, requirement for permanent residential care and unexpected serious adverse events. The study is registered under NCT00716079, ISRCTN73916115 and ACTRN12608000362392.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1" numbered="no"><p>Conflict of interest: None.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Delcourt</namePart><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Huang</namePart><affiliation>Department of Neurology, Peking University First Hospital, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Wang</namePart><affiliation>Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Heeley</namePart><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Lindley</namePart><affiliation>Sydney Medical School – Western, University of Sydney, Sydney, NSW, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Stapf</namePart><affiliation>Department of Neurology, European Regional Coordinating Centre, Clinical Research Unit, Lariboisière Hospital, APHP, Paris, France</affiliation><affiliation>INSERM Unit 708, APHP, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Tzourio</namePart><affiliation>INSERM Unit 708, APHP, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Arima</namePart><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Parsons</namePart><affiliation>John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Sun</namePart><affiliation>The George Institute, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Neal</namePart><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Chalmers</namePart><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Anderson</namePart><affiliation>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia</affiliation><affiliation>E-mail: canderson@george.org.au</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>for the INTERACT2 Investigators</namePart><description>The George Institute for International Health, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, AustraliaDepartment of Neurology, Peking University First Hospital, Beijing, ChinaShanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, ChinaSydney Medical School – Western, University of Sydney, Sydney, NSW, AustraliaDepartment of Neurology, European Regional Coordinating Centre, Clinical Research Unit, Lariboisière Hospital, APHP, Paris, FranceINSERM Unit 708, APHP, Paris, FranceJohn Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, AustraliaThe George Institute, Beijing, China</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2010-04</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="formulas">0</extent><extent unit="references">22</extent><extent unit="linksCrossRef">39</extent><extent unit="words">5342</extent></physicalDescription><abstract>Rationale: The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure lowering and effects on haematoma expansion within 6 h of onset of intracerebral haemorrhage. This article describes the design of the second, main phase, INTERACT2.</abstract><abstract>Aims: To compare the effects of a management strategy of early intensive blood pressure lowering with a more conservative guideline‐based blood pressure management policy in patients with acute intracerebral hemorrhage.</abstract><abstract>Design: INTERACT2 is a prospective, randomized, open label, assessor‐blinded end‐point (PROBE). Patients with a systolic blood pressure greater than 150 mmHg and no definite indication for or contraindication to blood pressure‐lowering treatment are centrally randomised to either of two treatment groups within 6 h onset of intracerebral haemorrhage. Those allocated to intensive blood pressure lowering will receive primarily intravenous, hypotensive agents to achieve a systolic blood pressure target of <140 mmHg within 1 h of randomisation and to maintain this level for up to 7 days in hospital. The control group will receive blood pressure‐lowering treatment to a target systolic blood pressure of <180 mmHg. Both groups are to receive similar acute stroke unit care, therapy and active management. Oral antihypertensive therapy is recommended in patients before hospital discharge with a long‐term systolic blood pressure goal of 140 mmHg according to secondary stroke prevention guidelines. A projected 2800 subjects are to be enrolled from approximately 140 centres worldwide to provide 90% power (α 0·05) to detect a 14% difference in the risk of death and dependency between the groups, which equates to one or more cases of a poor outcome prevented in every 15 patients treated.</abstract><abstract>Study outcomes: The primary outcome is the combined end‐point of death and dependency according to the modified Rankin Scale at 90 days. The secondary outcomes are the separate components of the primary end‐point in patients treated <4 hours of ICH onset, grades of physical function on the modified Rankin Scale, health‐related quality of life on the EuroQoL, recurrent stroke and other vascular events, days of hospitalisation, requirement for permanent residential care and unexpected serious adverse events. The study is registered under NCT00716079, ISRCTN73916115 and ACTRN12608000362392.</abstract><subject lang="en"><genre>keywords</genre><topic>blood pressure</topic><topic>clinical trial</topic><topic>hypertension</topic><topic>INTERACT</topic><topic>intracerebral haemorrhage</topic><topic>stroke</topic></subject><relatedItem type="host"><titleInfo><title>International Journal of Stroke</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1747-4930</identifier><identifier type="eISSN">1747-4949</identifier><identifier type="DOI">10.1111/(ISSN)1747-4949</identifier><identifier type="PublisherID">IJS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>110</start><end>116</end><total>7</total></extent></part></relatedItem><identifier type="istex">5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25</identifier><identifier type="ark">ark:/67375/WNG-HBDH7569-X</identifier><identifier type="DOI">10.1111/j.1747-4949.2010.00415.x</identifier><identifier type="ArticleID">IJS415</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2010 The Authors. Journal compilation © 2010 World Stroke Organization</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001198 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001198 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5EA288418DD3A1A2CAE9019ACEFFA211C31F7B25
|texte= The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)
}}
| This area was generated with Dilib version V0.6.33. |  |